Description

Blueprint Medicines Corporation is a precision medicine enterprise, dedicated to inventing therapeutic solutions for genetically characterized cancers and blood disorders. Its operations span both the United States and international markets. Currently, Blueprint is advancing AYVAKIT, prescribed for systemic mastocytosis (SM) and specific gastrointestinal stromal tumors. Its pipeline includes BLU-263, an orally administered, potent KIT inhibitor, designed to address non-advanced SM and other mast cell-related conditions. Another oral, potent inhibitor, Fisogatinib, is being developed for hepatocellular carcinoma. The firm also focuses on GAVRETO, targeting RET fusion-positive non-small cell lung cancer, various altered solid tumors, and medullary thyroid carcinoma. In the realm of non-small cell lung carcinoma (NSCLC), Blueprint is advancing BLU-701 and BLU-945 for cases driven by epidermal growth factor receptor mutations, alongside BLU-451 specifically for patients with EGFR exon 20 insertion mutations. Beyond oncology, the company is progressing BLU-782 for fibrodysplasia ossificans progressive, BLU-222 for cyclin E aberrant cancers, and BLU-852 for various advanced malignancies. Blueprint maintains partnerships and licensing deals with several entities, including Clementia Pharmaceuticals, Inc., Proteovant Therapeutics, CStone Pharmaceuticals, Genentech, Inc., F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., and Zai Lab (Shanghai) Co., Ltd. Founded in 2008, the company initially operated as Hoyle Pharmaceuticals, Inc., before rebranding to Blueprint Medicines Corporation in June 2011. Its corporate headquarters are situated in Cambridge, Massachusetts.